Overview
SER market data
Price History
SER price chart · 1M
- O
- 2.59
- H
- 2.60
- L
- 2.53
- C
- 2.58
- Vol
- 648.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $2.59
- Previous Close
- $2.67
- Day High
- $2.60
- Day Low
- $2.53
- 52 Week High
- $2.85
- 52 Week Low
- $1.55
- 7 Day Return
- -2.27%
- 30 Day Return
- +24.04%
- 90 Day Return
- +38.71%
- 1 Year Return
- +43.33%
- Daily Notional Volume
- $1.7K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 7.51 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,498.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.22 – $7.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $42.1M · P/B 69.50 · P/S 292.66.
Company News
8-K filing — Serina Therapeutics, Inc. (SER)SEC EDGAR · Aug 26, 2026, 10:24 PM
Serina Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 12,500,000 Shares Of Common Stock By Roth Principal InvestmentsBenzinga · Aug 24, 2026, 9:32 PM
Serina Therapeutics Q2 EPS $(0.55) Misses $(0.47) Estimate, Sales $130.000K, Same YoYBenzinga · Aug 13, 2026, 8:47 PM
Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s DiseaseBenzinga · Jul 23, 2026, 10:10 AM
Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's DiseaseBenzinga · Jul 9, 2026, 3:50 PM
BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8Benzinga · Jul 1, 2026, 12:00 PM
Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's DiseaseBenzinga · Jun 30, 2026, 1:10 PM